2/2
© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri
2/2
© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri
2/2
PARIS (Reuters) – French specialty vaccine company Valneva and U.S. healthcare giant Pfizer (NYSE:) said they had entered an equity subscription agreement under which Pfizer will invest 90.5 million euros ($95.24 million) in Valneva, representing 8.1% of its capital.
The deal comes through a reserved capital increase to further support the strategic Lyme partnership between the two companies, they added in a statement.
($1 = 0.9502 euros)
